Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Raised by Trust Point Inc.

Trust Point Inc. boosted its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,175 shares of the pharmaceutical company’s stock after acquiring an additional 59 shares during the quarter. Trust Point Inc.’s holdings in Vertex Pharmaceuticals were worth $473,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of VRTX. Edgewood Management LLC raised its position in Vertex Pharmaceuticals by 7,876.3% in the third quarter. Edgewood Management LLC now owns 1,546,370 shares of the pharmaceutical company’s stock worth $719,186,000 after acquiring an additional 1,526,983 shares in the last quarter. Jennison Associates LLC raised its position in Vertex Pharmaceuticals by 18.1% in the third quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock worth $2,581,373,000 after acquiring an additional 851,054 shares in the last quarter. Wellington Management Group LLP raised its position in Vertex Pharmaceuticals by 17.2% in the third quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company’s stock worth $2,231,858,000 after acquiring an additional 704,421 shares in the last quarter. Assenagon Asset Management S.A. raised its position in Vertex Pharmaceuticals by 169.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 839,672 shares of the pharmaceutical company’s stock worth $338,136,000 after acquiring an additional 528,029 shares in the last quarter. Finally, International Assets Investment Management LLC raised its position in Vertex Pharmaceuticals by 74,015.5% in the third quarter. International Assets Investment Management LLC now owns 324,626 shares of the pharmaceutical company’s stock worth $150,977,000 after acquiring an additional 324,188 shares in the last quarter. 90.96% of the stock is currently owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX opened at $488.44 on Thursday. The company has a market capitalization of $125.79 billion, a PE ratio of -245.45, a price-to-earnings-growth ratio of 2.39 and a beta of 0.41. The company’s fifty day moving average price is $435.03 and its 200 day moving average price is $462.56. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. During the same quarter in the previous year, the firm posted $3.67 earnings per share. Vertex Pharmaceuticals’s revenue was up 11.6% compared to the same quarter last year. As a group, analysts expect that Vertex Pharmaceuticals Incorporated will post -1.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on VRTX shares. Oppenheimer cut Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. Raymond James reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, October 10th. HC Wainwright lifted their price target on Vertex Pharmaceuticals from $535.00 to $550.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Scotiabank lifted their price target on Vertex Pharmaceuticals from $430.00 to $433.00 and gave the stock a “sector perform” rating in a research note on Friday, January 31st. Finally, Royal Bank of Canada lifted their price target on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a sell rating, nine have given a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $502.58.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.